Bayesian design and analysis of active control clinical trials

Biometrics

Volumn 55, Issue 2, 1999, Pages 484-487

  Simon, Richard ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Active control trials; Bayesian; Clinical trials; Equivalence trials

Indexed keywords

CONTROLLED DRUG DELIVERY; STATISTICAL TESTS;

ACTIVE CONTROL; ACTIVE CONTROL TRIAL; BAYESIAN; BAYESIAN ANALYSIS; BAYESIAN DESIGN; CLINICAL TRIAL; CONTROL TREATMENTS; DESIGN AND ANALYSIS; EQUIVALENCE TRIAL; NULL HYPOTHESIS;

BAYESIAN NETWORKS;

ARTICLE; BAYES THEOREM; HYPOTHESIS; METHODOLOGY; STATISTICAL ANALYSIS; STATISTICAL MODEL;

ANGINA;

EID: 0032968433     PISSN: 0006341X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0006-341X.1999.00484.x     Document Type: Article

References (7)

1. Blackwelder, W. (1982). Proving the null hypothesis in clinical trials. Controlled Clinical Trials 3, 345-353.
2. Durrleman, S. and Simon, R. (1990). Planning and monitoring of equivalence studies. Biometrics 46, 329-336.
3. Fleming, T. (1990). Evaluation of active control trials in AIDS. Journal of Acquired Immune Deficiency Syndromes 3, S82-S87.
4. Gould, A. (1991). Another view of active-controlled trials. Controlled Clinical Trials 12, 474-485.
5. Makuch, R. and Simon, R. (1978). Sample size requirements for evaluating a conservative therapy. Cancer Treatment Reports 62, 1037-1040.
6. Oler, A., Whooley, M. A., Oler, J., and Grady, D. (1996). Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. Journal of the American Medical Association 276, 811-815.
7. Temple, R. (1983). Difficulties in evaluating positive control trials. Proceedings of the American Statistical Association (Biopharmaceutical Section) 1-7.